ArticleJournal of gastroenterology and hepatology2026
Association Between ADH1B rs1229984 Genetic Polymorphism and Hepatic Steatosis Assessed by CT Attenuation: A Mediation Analysis of Central Obesity in MASLD.
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
BACKGROUND AND
aimsADH1B genetic variants have recently emerged as a novel genetic determinant of metabolic dysfunction-associated steatotic liver disease (MASLD); however, their clinical significance in Asian populations is unclear.
methodsWe used multivariable logistic regression to evaluate the association between ADH1B genetic variants and MASLD risk and mediation analysis to quantify the direct effects of ADH1B polymorphisms and the indirect effects mediated by central obesity.
resultsThe AA genotype was associated with lower waist circumference (81.9 ± 11.0 cm) and higher liver computed tomography (CT) attenuation (58.7 ± 9.3 HU) compared with the AG (84.1 ± 11.1 cm; 56.9 ± 9.4 HU) and GG (84.7 ± 9.6 cm; 54.0 ± 9.8 HU) genotypes. Compared with the AA genotype, the GG and AG genotypes were associated with a higher MASLD risk by both ultrasonography (GG: OR = 3.97, 95% CI: 1.68-9.38, p = 0.002; AG: OR = 1.97, 95% CI: 1.16-3.35, p = 0.012) and CT criteria (GG: OR = 3.98, 95% CI: 1.75-9.02, p = 0.001; AG: OR = 2.33, 95% CI: 1.47-3.69, p < 0.001). Waist circumference mediated 17.4% and 30.2% of the associations between the ADH1B dominant genotype and MASLD by CT liver-to-spleen attenuation ratio < 1.0 and ultrasonography. Waist circumference accounted for 39.7% of the association between the ADH1B dominant genotype and hepatic steatosis assessed by liver CT attenuation.
conclusionsADH1B variants were associated with MASLD, and mediation analysis demonstrated a statistical mediation pattern involving waist circumference that was consistent with a hypothesized adipose-liver pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.